A large observational study of one-thousand ET patients showed that nearly 90% had mutations in one of three key driver genes, which are mutually exclusive: JAK2 (62%), CALR (27%), and MPL (3%), with 8% being triple-negative [19]. The gene discussed is JAK2; the disease is essential thrombocythemia.